文献速递药物不良反应与药物警戒特殊人群用药

津巴布韦黑人乳腺癌患者多柔比星心脏毒性及药物基因组学研究

Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients.
PubMed 文献 · Br J Clin Pharmacol · 2023-01-27

该队列研究纳入50例接受多柔比星治疗的津巴布韦黑人乳腺癌患者,随访12个月并行系列超声心动图及UGT1A6*4、SLC28A3、RARG基因分型。

要点

  • SLC28A3、UGT1A6*4、RARG变异频率与其它人群不同。
  • 三个基因变异均未显示与多柔比星心脏毒性的关联。

研究设计与样本

  • 前瞻性队列研究,纳入50例接受多柔比星治疗的津巴布韦黑人乳腺癌患者,随访12个月,行系列超声心动图和基因分型。

主要发现

  • SLC28A3(rs7853758)、UGT1A6*4(rs17863783)和RARG(rs2229774)的变异频率分别为60.7%、17.9%和14.3%。
  • 未观察到多柔比星心脏毒性与上述三个基因变异之间的关联。

关键数值与推荐

  • SLC28A3(rs7853758)频率60.7%,UGT1A6*4(rs17863783)频率17.9%,RARG(rs2229774)频率14.3%。

临床怎么用

  • 在津巴布韦黑人乳腺癌患者中,多柔比星心脏毒性监测仍需按临床常规进行。
  • 现有三个基因变异尚不能作为该人群多柔比星心脏毒性的预测标志物。

局限性

  • 样本量较小(50例),随访时间12个月,可能不足以检测基因与心脏毒性的关联。
  • 未来需更大样本量和更长随访时间的研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Doxorubicin-induced cardiotoxicity (DIC) is a significant cause of mortality in cancer care. This study was conducted to establish the frequency of DIC in Zimbabwean breast cancer patients on doxorubicin and to test the DIC predictive power of genetic biomarkers. METHODS: A cohort of 50 Zimbabwean breast cancer patients treated with doxorubicin were followed up for 12 months with serial echocardiography and genotyped for UGTA1A6*4, SLC28A3 and RARG. Eleven per cent of the patients experienced DIC. RESULTS: The frequencies of SLC28A3 (rs7853758), UGT1A6*4 (rs17863783) and RARG (rs2229774) were 60.7%, 17.9% and 14.3%, respectively. No association between DIC and the three variants was observed. CONCLUSIONS: This is the first study on the prevalence of DIC and associated genetic biomarker predictive evaluation in Zimbabwean breast cancer patients. The genetic frequencies observed in our study were different to those reported in other populations. A larger sample size with a longer follow-up time will be necessary in future studies.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Nyangwara VA, Mazhindu T, Chikwambi Z, et al. Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients. Br J Clin Pharmacol. 2023. PMID: 36630266. doi:10.1111/bcp.15659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。